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Prostate cancer is one of the most common cancers in men worldwide. Therefore, identification of specific biomarkers 
for early dignosis are crucial prerequisites for efficient treatment of patients. We investigated alterations in the 
physicochemical characteristics of blood plasma proteins from men with prostate tumors, and its diagnostic significance 
with the identified alterations. Blood plasma of patients with benign hyperplasia of the prostate (BHP), BHP with high-grade 
prostatic intraepithelial neoplasia (HGPIN) regions and Cancer of Prostate (CaP) were used. Spectroscopic and SDS-PAGE 
methodologies were utilized for examining alterations in the physicochemical characteristics of blood plasma proteins. 
Relationship between alterations of the first-peak fluorescence intensities and prostate tumor progression was observed. 
Also, increased intensity of the second-peak corresponding to nicotinamide co-enzymes (NADH and NADPH) was noted in 
BHP-with-HGPIN and CaP specimens. The main peak maximum (Td) was observed at 66-67°C in BHP plasma and at 63-
64°C in BHP-with-HGPIN regions and CaP. In BHP and BHP-with-HGPIN regions, an arm was noted at 70-71°С. The 
portions of thermostable proteins (acute phase proteins) were increased and modified proteins were formed in plasmas 
during the malignant transformation. Recorded fluorescence spectra allowed to differentiate prostate tumors and determine 
the disease progression. Differential scanning calorimetry markedly differentiated benign BHP-with-HGPIN regions and 
CaP, which shows the diagnostic importance of the method.  
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Cancer of prostate (CaP) is the most common cancer 
and one of the leading causes of death in men 
worldwide
1
. Prostate cancer incidence and mortality 
rates are strongly related to the age with the highest 
incidence being seen in elderly men (>65 years of 
age)
2
. However, recent statistics point to an increased 
incidence of the disease in men aged under 55 
years
3,4
. In this group, presumably specific type of 
energy metabolism of prostate peripheral epithelial 
cells should also be taken into account.
. 
Prostate 
cancer is a disease model of great interest from a 
metabolic perspective as prostatic tissue exhibits 
unique metabolic activity under baseline conditions
5
. 
Notably, prostate cancer is a heterogeneous disease 
characterized by different clinical behaviour, from 
indolent to aggressive tumors with lethal progression. 
Therefore, early diagnostics and identification of 
prostate cancer aggressiveness are crucial 
prerequisites for efficient treatment of patients
6
. Early 
detection of prostate cancer using prostate-specific 
antigen (PSA) in blood reduces death among the 
unscreened men. However, due to the relatively 
modest specificity of PSA at commonly used cut-offs, 
there are urgent needs for additional and more specific 
biomarkers contributing enhanced risk classification 




Thus, early detection/diagnosis of the disease is not 
optimal yet, since complete and complex diagnostic 
tests, which can detect prostate tumors on the initial 
stage are not available yet. As a result, up to 60-80% 
of the CaP patients are diagnosed with progressed and 
metastatic cancer by the time of its clinical 
manifestations
8
. As noted, the development of newer 
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diagnostic methods for detection and therapy of early 
and progressed CaP remains one of the major issues 
in modern urologic medicine. The clinical and 
fundamental research in prostate cancer is currently 
entering the proteomic and genomic era. The focus 
has switched from single marker (e.g., PSA) to panels 
of biomarkers (including heat shock proteins and 
blood plasma proteins). A number of comparative 
proteomic studies have been carried out to find 
specific diagnostic biomarkers able to distinguish 
prostate cancer from benign prostatic hyperplasia 
(BPH) as well as indolent from aggressive cancers. 
Novel genetic markers [such as transmembrane 
protease serine 2 (TMPRSS2)-ERG fusion gene 
mRNA] or prostate cancer gene 3 (PCA3) had already 
entered the clinical practice
6
. A new trend in 
serum/plasma biomarker search is to go beyond 
protein, in search of circulating tumor cells or 
circulating genetic material (DNA, miRNA). 
However, due to their abundance, proteins still hold 




Human blood plasma is a complex biological 
system, containing thousands of proteins and 
peptides, which have been isolated and studied using 
various physical and biochemical methods, including 
differential scanning calorimetry (DSC)
9
, The study 
of blood plasma/serum of the patients with tumors 
showed strong differences in plasma/serum protein 
thermostability compared to the normal, as confirmed 




Therefore in this study, we examined potential 
alterations in the physicochemical characteristics of 
blood plasma proteins in men with prostate tumors 
and also tried to establish the specificity and possible 
diagnostic significance of the detected changes.  
 
Material and Methods 
In order to study the above objective we used three 





, which allowed us to 
differentiate prostate tumors and discuss the degree of 
cancer progression; and gel electrophoresis
12
 (for 
protein fragmentation in polyacrylamide gel), which 
allowed us to detect and analyze tumor specific proteins, 
and also to demonstrate basic alterations in the plasma 
proteins in blood of men with prostate tumors. 
 
Samples 
Blood plasma of the patients with benign 
hyperplasia of the prostate (BHP), the BHP with high-
grade prostatic intraepithelial neoplasia (HGPIN) 
regions and Cancer of Prostate (CaP) served as 
materials for this study. Each study group consisted of 
15 patients of ages 60-75 year. The control group 
consisted of 15 healthy men of the same age group. 
Patients were not receiving any type of 
medication/treatment during the sample collections 
for this investigation. 
 
The Ethics Committee of Georgia approved the 
study and informed consent was obtained from each 
patient with BHP, the BHP-with-HGPIN regions, 
Cap, and the control groups. The blood specimens 
were obtained before the transurethral resection of the 
prostate (TURP) at the National Centre of Urology 
(Georgia). Clinical stage of the disease was diagnosed 
by the same Center by means of rectal, histological, 
and echographic examinations of the prostate gland. 
Histological analyses of the TURP-derived specimens 
were performed by the uropathologist at the Urology 
National Centre, Georgia.  
 
Blood samples (10 mL each) were rinsed with  
1.0 mL of heparin (5000 ME; 1 ME=0.0077 mg of 
heparin). The blood was centrifuged at 3000 rpm for 
15 min to obtain the clear plasma. 
 
Blood plasma fluorescence spectroscopy 
Optical spectroscopic methods are widely used in 
cancer research today
13
. For example, fluorescence 
spectroscopy, which can be used in the evaluation of 
pre-cancerous and cancer processes in vivo, deserves 
special attention since it is non-invasive, quick and 
highly informative. Analysis of fluorescence spectra 
allows quantitative and qualitative evaluation of 
various substances as well as detection of their 
conformational changes. Application of fluorescence 
method may improve diagnosis and therapeutic 




For blood plasma fluorescent measurements, blood 
samples were taken before the surgery. A 0.5 mL 
plasma was diluted with 2.0 mL distilled water, and 
the diluted plasma sample was placed in a 
spectroscopic quartz minicuvettes. These cuvettes 
were free of absorption and emission in the spectral 
range of interest (300-600 nm). Fluorometric 
measurements were made using a Spectrofluoro-
photometer (model MPF-3), using the excitation 




Differential scanning calorimetry (DSC) 
The measurements were performed using a DSC 
with sensitivity of 0.1 µW
10
. Volumes of the 
measuring vessels varied from 0.03 to 0.1 cm
3
; the 




chosen heating rate was 0.75°C per min, and the 
temperature range of measurements was from 40 to 
100°C. The accuracy of the temperature measurements 
was ≤0.05°C. The error in the determination of the 
melting enthalpy (ΔHd) and heat capacity dQ/dT 
(ΔCd) did not exceed 10%. The microcalorimetery 
data processor was equipped with the software needed 
for determination of the melting thermodynamic 
parameters of blood plasma specimens, and the 
calorimetric curves were thus plotted and deconvoluted 
with Origin 9.0. 
 
Gel electrophoresis 
Electrophoresis was carried out according to  
the method of Laemmli
12,14
, using 10-25% poly-
acrylamide gel (2 mm) and 0.1% sodium dodecyl 
sulphate (SDS), with an SE-200 (Hoefer Scientific 
Instruments) over a period of 3.5 h with 2 mA 
electrical current. High molecular weight standard 
proteins were used as markers for electrophoresis: 
thyroglobulin (330 kD), catalase (60 kD), lactate 
dehydrogenase (36 kD), and ferritin (18.5 kD). The 







Fluorescence studies of blood plasma 
First, we investigated the physical and chemical 
alterations occurring in the blood of patients with 
BHP, the BHP-with-HGPIN4-5 regions and CaP. This 
includes the assessments of alterations in the first- and 
second-fluorescence peak intensities corresponding to 
dysproteinemia and the reduced redox co-enzymes 
(NADH and NADPH) in plasma samples using the 
spectro-fluorometric method to establish the 
specificity of alterations occurring in plasma, and also 
to determine whether any metabolic alterations 
specific to prostate tumors could be reflected in the 
composition of blood plasma. 
 
Fluorescence spectra of plasma in the ultraviolet 
and visible regions (340-470 nm) showed a clear 
difference between the control group and patients 
with prostate tumors. Two peaks of fluorescence 
characteristics to plasma were observed in the control 
group (Fig. 1) as well as in men with prostate tumors 
(Fig. 2). However, in relation to prostate tumors, the 
intensity of the first peak increased in the following 
order: control group (Fig. 2A) → BHP (Fig. 2B) → 
BHP-with-HGPIN regions (Fig. 2C) → CaP (Fig. 
2D). The intensity of the first peak was found to be 
highest in case of CaP (Fig. 2D). As for the second-
peak, its intensity was sharply decreased in plasma of 
BHP patients as compared to the control group  
(Fig. 2A). In case of BHP-with-HGPIN regions, the 
second peak clearly expressed increased intensity 
(Fig. 2C). In plasma of CaP patients, the second 
peak’s fluorescence had increased (Fig. 2D), but 
shifted in the direction of the short wave length 
(~440-460 nm) and plateaued. 
 
Differential scanning calorimetry studies 
We utilized the DSC method to study the thermo-
dynamic parameters of the plasma proteins (albumins, 
’acute phase’ proteins) in patients with prostate 
tumors. In particular, temperature corresponding to the 
maximum of the main peak on the denaturation curve 
(Td), existence of the peaks and arms, and denaturation 
heat (Q) were examined. Based on the results, we 
attempted to evaluate the specificity of the detected 
alterations and possible diagnostic significance of the 









Fig. 2 — Fluorescence spectra of the blood plasma of the men 
with prostate tumors. (A) Control group; (B) Benign hyperplasia 
of prostate (BHP); (C) BHP with high-grade prostatic 
intraepithelial neoplasia (HGPIN) regions; and (D) Cancer of 
prostate (CaP) 
 




the degree of prostate tumor progression. We found 
that the temperature corresponding to the plasma main 
peak maximum was 60-61°C on the calorimetric 
curve of the control group (Table 1; Fig. 3A). The Q 
or change of enthalpy (ΔH) was determined to be 
18±0.5 J in the given case (Table 1). 
 
On the calorimetric curve of BHP patients, 
temperature of the main peak (Td) was shifted in the 
direction of high temperature range (66-87
°
C), with a 
small arm in the range of 70-71°C (Fig. 3B; Table 1). 
The denaturation heat of plasma albumins (Q) was 
also studied in BHP patients, which did not change 
(19±0.5 J) compared with the control group (Table 1). 
 
In the patients with BHP-with-HGPIN regions, 
altered temperature of the main peak maximum (Td) 
on the calorimetric curve of blood plasma was noted 
(the observed value was higher than the control group 
but lower than the BHP group; 63-64°C). Interestingly, 
an additional arm, was absent in the control and BHP 
groups, which was detected in the range of 58-59°C 
of patients with BHP-with-HGPIN regions, as well as 
the arm in the range of 70-71°C (Fig. 3, Table 1). The 
Q value in patients with BHP-with-HGPIN regions 
was 20 ±0.5 J, which changed slightly compared to 
the same index in BHP patients, and was more 
distinctly expressed as compared to the control group 
(Table 1). 
On the calorimetric curve of the plasma of patients 
with CaP, the temperature interval (corresponding to 
the main peak maximum) was 63-64°C (Fig.3D), 
similar to that of patients with BHP-with-HGPIN 
regions. However, this arm was not found in 
temperature interval of 70-71°C. On the calorimetric 
curve of patients’ plasma with CaP (Fig. 3D), instead 
of the arm in temperature interval 58-59°C, a visible 
peak was detected (Table 1). The Q value in this case 
was 24±0.5 J, which was increased as compared to all 
other experimental groups. 
 
SDS-PAGE studies 
We investigated the qualitative and quantitative 
alterations in protein fractions in blood plasma of men 
with prostate tumors utilising gel-electrophoresis 
(SDS-PAGE). The following protein fractions were 
observed on the electropherogram (Fig. 4) of control 
group, BHP, the BHP-with-HGPIN and CaP patients: 
220, 135, 98, 88, 68-70, 53-62, 46, 41, 38, 32, 27, 25 
and 14 kD. 
 
We found an increase of 220 kD protein fraction in 
all experimental groups as compared to the control 
group; however, the difference was relatively smaller 
in case of CaP. The amount of 135 and 88 kD proteins 
increased in parallel with the progression of the 
disease (control group  BHP  BHP-with-HGPIN 
 CaP) (Fig. 4). While the 98 kD fraction was not 
found in the control or BHP and CaP groups, but it 
was revealed in the BHP-with-HGPIN regions. The 
analysis also showed an increase of 88 kD fraction 
with the progression of the disease as compared to the 
control group. The levels of 68 kD fraction were 
increased in the following order: control group  
CaP  BHP  BHP-with-HGPIN regions. The 
sharpest increase of the given fraction (i.e., 68 kD) 
was found in case of BHP-with-HGPIN. The fraction 




Fig. 3 — Calorimetric curves of the blood plasma of men with prostate tumors. (A) Control group; (B) Benign hyperplasia of prostate 
(BHP); (C) BHP with high-grade prostatic intraepithelial neoplasia (HGPIN) regions; and (D) Cancer of prostate (CaP) 
 
 
Table 1 — Thermodynamic parameters of blood plasma proteins 









Control group - - 60-61 18±0.5 
BHP 70-71 - 66-67 19±0.5 
BHP with HGPIN 58-59; 70-71 - 63-64 20±0.5 
Prostate cancer (CaP) - 58-59 63-64 24±0.5 
[BHP, Benign hyperplasia of prostate; HGPIN, High-grade prostatic 
intraepithelial neoplasia; dT, temperature change; ΔH, melting 
enthalpy; Q (J), heat (Joule). Accuracy of temperature measurements 
was ≤0.05°C] 
 




the plasma proteins, which was increased with the 
following pattern: control group  BHP-with-HGPIN 
 CaP  BHP. As for the low molecular weight 
fractions (such as 41, 38 and 32 kD), these were not 
found in the control group and CaP patients, but were 
detectable in smaller amount in cases of patients with 
BHP and the BHP-with-HGPIN regions (Fig. 4). 
 
Discussion 
Charateristically, it is recognized that there are two 
fluorescence peaks to blood plasma of healthy men 
(Fig. 1). The first peak corresponds to blood plasma 
proteins (at 340-360 nm) and the second peak 
corresponds to the reduced nicotinamide co-enzymes 
(at 450-470 nm)
13
. The ratio of the intensity of these 
peaks is an important characteristic of the functional 
state of the organism
15
. Increase in the first 
fluorescence peak intensity in patients with prostate 
tumors may be the result of dysproteinemia, which 
implies the formation and increased concentration of 
cancer embryonic, or ”acute phase” proteins (e.g., 
orosomucoid, α1-antitrypsin, haptoglobin and C-
reactive protein) associated with tumor growth
16
. The 
increase in the peak intensity may also be caused by 
the modified forms of the mentioned proteins
9
, 
increase of α- and β- globulin concentrations, 
decrease of native albumin concentration and increase 
of the so called modified albumin levels in blood 
plasma
16
. Thus, the increase in the tumor-specific 
proteins in blood of patients with prostate tumors 
fairly coincides with the literarture data, which may 
indicate the tumor-specificity of the obtained results. 
 
The formation (or increased level) of all the above 
mentioned proteins is considered from two points of 
views: (i) the response of an organism to the tumor 
growth; and (ii) as a localized reaction in response to 
the infiltration of the normal tissue by the tumor cells. 
We presume that the tumor progression together with 
the increased concentration of ’acute phase’ proteins 
may be caused by the release of lysosomal hydrolases, 
which stimulate the formation of blocking anti-
proteases (e.g., α1-antitrypsin, α1-antichymotrypsin) 
from the destructed tumor and non-tumor cells. The 
other cause may be due to inflammation process, 
which accompanies the tumor cell proliferation
16
. 
Thus, a direct relationship between the alterations of 
the first peak fluorescence and prostate tumor 
progression was observed in our assessments. 
 
The decrease of the second peak intensity in 
patients with BHP (Fig. 2B) compared to the control 
group (Fig. 2A) may be caused by the increased 
enzyme activity on the background of BHP (glucose-
6-phosphate dehydrogenase, NADH-oxidase, and 
cytochrome P450, etc.) and subsequent increased 
utilization of nicotinamide coenzymes
17




Fig. 4 — Electropherogram of blood plasma proteins in SDS–polyacrylamide gel in men with prostate tumors. Standard proteins:  
(i) Thyroglobulin (330 kD); (ii) Catalase (60 kD); (iv) Lactate dehydrogenase (36 kD); and (iv). Ferritin (18.5 kD).  
(A) Electropherogram of the membrane proteins of the control group erythrocytes; (B) Electropherogram of erythrocyte membrane 
proteins of the patients with benign hyperplasia of prostate (BHP); (C) Electropherogram of erythrocyte membrane proteins of the 
patients with BHP with high-grade prostatic intraepithelial neoplasia (HGPIN); and (D) Electropherogram of erythrocyte membrane 
proteins of the patients with cancer of prostate (CaP) 
 




that the synthesis and metabolism of these substances 
might be impaired in pathological conditions (even in 
BHP)
13,15
. In cases of BHP-with-HGPIN regions and 
CaP, the increased intensity of the second-peak 
corresponding to nicotinamide co-enzymes may be 
caused by the tumor development and malfunction of 
the enzyme systems in parallel with the disease 
progression, and as a result, nicotinamide co-enzymes 
accumulated in the blood plasma
17
. In addition, the 
increased intensity of the second-peak may also be 
caused by the alterations in the energy metabolism of 
tumor cells. It is established that unlike other 
hormone-dependent tumors, prostate epithelial cells 
have specific energy metabolism
5
. According to the 
peer-reviewed literature data, changes of nicotinamide 
co-enzyme containing enzyme activities may also be 
caused by the altered intensity of lipid peroxidation in 
blood
18
. Thus, the fluorescence study of the blood 
plasma allowed us to study the living system in vivo 
without disturbing the structure-functional integrity 
and interrupting natural processes occuring in the 
organisms. Moreover, the given spectra allowed us to 
differentiate prostate tumors and discuss the extent of 
the disease progression. 
 
On the calorimetric curve of the control group 
plasma (recorded by DSC), main peak maximum was 
revelead in the interval between 60-61°C, which 
coincides with the literature data and corresponds to 
the denaturation temperature of native albumin 
(60.5°C)
13,23
. In the case of plasma of BHP patients, 
the shift of the main peak maximum towards the 
higher temperature range (66-67°C) may be a result of 
the increased ’acute phase’ protein levels during the 
tumor development
16,18
. Formation of the small arm at 
70-71°C is presumably associated with the increased 
immunoglobulin concentrations in blood plasma
16
, 
which fully corresponds to the histomorphological 
diagnosis of prostate benign hyperplasia with 
inflammatory changes. Thus, the formation of this 
small arm may be associated with the enhanced 
protective function of an organism, and intensification 
of the immunoglobulin synthesis during the 
inflammation process. In case of the BHP-with-
HGPIN reigons, shift of the main peak maximum (Td) 
towards the higher temperature range of 63-64°C may 
be caused by the decreased level of native albumin. 
Appearance of an additional arm (58-59°C) in this 
case may also be associated with the progression of 
the disease, formation of HGPIN regions, and 
increased level of the modified albumin
16
. 
In case of CaP patients, the peak in the 
temperature interval of 58-59°C on the calorimetric 
curve of plasma (Table 1) may be the result of an 
even sharper increase in the modified albumin 
portion in the overall albumin fraction. Additionally, 
it is worth noting that the arm at 70-71°C range was 
not detectable in the given case, which may be a 
result of tumor metastasis [as supported by the 
tumor, node, metastasis (TNM) staging/clinical data] 
and supressed immune system. Thus, we presume 
that in blood plasma of men with BHP and BHP-
with-HGPIN, the arm in temperature interval of  
70-71°C is specific and points to the inflammatory 
processes on the background of the noted disease. As 
for the temperature interval 63-64°C corresponding 
to the main peak (Td) maximum in BHP-with-
HGPIN and CaP plasmas, it should point to high risk 
of malignant transformation in men. Thus, the 
increased ratio of the thermostable proteins (acute 
phase proteins) and appearance of the modified 
forms of these proteins in blood plasma occurs along 
with the disease progression. This is reflected in the 
increased thermostability of the given system, which 
points to the degree of orderliness in the system. 
Therefore, the method of DSC makes it possible to 
differentiate healthy men from the patients with 
prostate tumors and to evaluate the degree of disease 
progression. 
 
Based on the peer-reviewed literature, 220 kD 
protein fraction may be represented by the α1-
globulin fraction (α1-lipoproteins) and γ-globulins. 
Moreover, the mentioned protein levels are also 
increased during the carcinogenesis and inflammatory 
processes
15,16
. It is known that BHP and the BHP-
with-HGPIN regions develop and progress on the 
background of inflammatory process. This hypothesis 
is supported by the emergence of the small arm in the 
temperature range of 70-71°C on the calorimetric 
curve of BHP plasma (Fig. 4B), which may be due to 
the result of enhanced protective function of the 
organism and corresponding intensification of 
immunoglobulin synthesis
16,20
. We presume that the 
decrease of 220 kD protein fraction in case of CaP as 
compared with prostate benign tumor may be the 
result of inflammatory process being overriden by the 
malignant tumor, which causes the inhibition of γ-
globulin synthesis and deterioration of the immune 
system of the organism. This hypothesis is supported 
by the disappearance of the small arm in the 
temperature interval of 70-71°C corresponding to 




immunoglobulins (on the calorimetric curve of CaP 
patients, Fig. 3D). 
 
It is reported that the tumor specific marker 
kallikrein-2 (hK2), with the molecular weight of 30 
kD, is released from the tumor tissue and circulates in 
blood as a free form or bound to the plasma proteins 
(such as α1-macroglobulin, protein C1-inactivator, 
and α-antitrypsin, etc.)
21
. It is also known that hK2 
forms a 135 kD fraction with blood plasma C1-
inactivator protein. We presume that the observed 135 
kD fraction is a complex of hK2-protein and C1-
inactivator. Moreover, it is known that hK2 protein 
levels are increased in case of CaP, alongside the 
mentioned complex concentrations
7,21
, which could be 
the reason for the increased 135 kD fraction in case of 
CaP in our study. Thus, 135 kD fraction, observed in 
our experiments, may serve as one of the 
specific/prognostic markers for prostate tumors. 
 
It is known that haptoglobin belongs to 98 kD 
proteins that binds to cathepsins B, H, T and 
hemoglobin (released as a result of erythrocyte 
hemolysis) and transport them out of the organism
22
. 
It is established that BHP-with-HGPIN regions 
contain cancerous, as well as necrotic sections, and 
suggested that BHP-with-HGPIN regions are the 
precursor of prostate transitory cell type cancer
23
. It is 
known that in case of BHP-with-HGPIN regions, 
necrotic sections are formed alongside the enhanced 
blood hemolysis. As a result, hemoglobin is released 
in high concentrations and haptoglobin synthesis is 
intensified in response
22
. This process is responsible 
for the withdrawal of any unneccessary hemoglobin 
from the organisms. In case of prostate BHP-with-
HGPIN regions, 98 kD mass protein fraction, as 
observed in our study, may be the manifestation of 
intensive haptoglobin synthesis. 
 
It is demostrated that hK2 also forms another 80 
kD complex with other blood plasma proteins (protein 
C inhibitor and α2-antiplasmin)
22
. Thus, it may be 
hypothesized that the 88 kD fraction observed in our 
study consists of the referred complexes of hK2 and 
plasma proteins. Moreover, the literature data shows 
that prostate-specific antigen (PSA) forms 90 kD mass 
complex with α1-antichymotrypsin
24
. Accordingly, the 
88 kD fraction may contain both hK2-protease 
inhibitors and PSA protease inhibitors. Considering 
that increased PSA level is characteristic of CaP, it is 
clear that the 88 kD fraction is also increased in case of 
prostate tumors as compared with the control group. It 
is likely that the increased portion of the 88 kD fraction 
is a manifestation of the increased PSA complex 
concentration, rather than the hK2 concentration. 
 
According to the literature reports, a large part of 
68 kD protein fraction belongs to plasma albumin, 
which may be similar to the molecular-weight protein 
α1-antichymotrypsin (68 kD) in this fraction
22
. 
Moreover, albumin (a ~66 kD protein) overrides other 
proteins in 50-70 kD fraction, which has been 
observed on the electropherogram of albumin-free 
plasma proteins
17,25
. In our case of plasma of patients 
with BHP and the BHP-with-HGPIN regions, several 
peaks were detected on the protein electropherogram 
(67-70 kD fractions), presumably these peaks 
correspond to several protein fractions, which were 
not revealed in our control or CaP groups. This 
finding supports our hypothesis that proteins, other 
than albumin, may exist in this fraction. Thus, in 
cases of BHP and the BHP-with-HGPIN regions, an 
increased 68 kD fraction is not caused by albumin (it 
must be taken into account that in case of tumor, 
albumin levels decrease insignificantly or do not 
change at all
16
), but with other proteins of the blood 
plasma (e.g., 1-antichymotrypsin, etc.) having 
similar molecular-weight
20
. The decrease of the noted 
fraction in CaP patients, compared to the patients with 
benign tumors, may be caused by the reduced levels 
of albumin
16
 and 1-antichymotripsin, which may be 
a result of the overriding inflammatory processes by 
tumor. It is also shown that modified albumin is 
found, and its portion is often increased in the 
albumin fraction of plasma in case of different 
pathologic conditions, including cancer
15
. Existence 
of the modified albumin in plasma of patients with 
BHP and CaP was verified by our data obtained by 
calorimetry determinations of plasma proteins (Fig. 3). 
 
It is noted that albumin found in blood of oncologic 
patients binds to carbohydrate components, such as 
fucose
25
. We presume that the appearance of 78 kD 
fraction in case of CaP, which is absent in both the 
control and BHP groups, is caused by the formation 
of the modified albumins. We also speculate that the 
78 kD fraction may cause the decrease of 68 kD 
fraction in case of CaP. Based on the peer-reviewed 
literature, 63-65 kD fraction consists of light- and 
heavy-chains of immunoglobulins - lgA and lgG1, 
G2, G3 (lgA, α1: 56-58 kD, α2: 52-54 kD), as well as 
of α-2-HS-glycoprotein (MW=58 kD, heavy chain: 53 
kD, light chain: 5 kD)
26
. This assumption is supported 




by our data obtained by the calorimetric method as 
well (arm at 70-71
0
C; Fig. 3B, 3C). Increased 
immunoglobulin concentrations in patients with BHP 
and the BHP-with-HGPIN regions compared to the 
control may be a result of the enhanced immune 
reponse of an organism to the inflammatory processes 
that accompany carcinogenesis. Decrease in 63-65 kD 
fraction on the plasma electropherogram in case of 
CaP, as compared to prostate benign tumors, may be a 
result of immunodeficiency caused by the pathology, 
as well as of the decrease in acute phase protein levels 






In this study of the plasma of prostate tumor 
patients, we observed: (i) direct relationship between 
the alterations of the first peak fluorescence inensities 
and prostate tumor progression; (ii) increased first 
peak intensity in case of prostate tumors, which may 
be caused by the elevated levels of ’acute phase’ 
proteins associated with tumor growth, as well as by 
the appearance of cancer embryonic antigen, and 
formation of modified albumin in the albumin fraction 
of blood plasma; and (iii) increased intensity of 
second peak corresponding to nicotinamide co-
enzymes (NADH and NADPH)in case of benign 
hyperplasia of the prostate (BHP) with high-grade 
prostatic intraepithelial neoplasia (HGPIN) and 
Cancer of Prostate (CaP). This may be the result of 
enzyme system malfunction in parallel with the 
disease progression, which results in the accumulation 
of the mentioned co-enzymes and alteration of energy 
metabolism in cancer cells. 
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